165 related articles for article (PubMed ID: 21685474)
1. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
Such E; Cervera J; Terpos E; Bagán JV; Avaria A; Gómez I; Margaix M; Ibañez M; Luna I; Cordón L; Roig M; Sanz MA; Dimopoulos MA; de la Rubia J
Haematologica; 2011 Oct; 96(10):1557-9. PubMed ID: 21685474
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.
Sarasquete ME; García-Sanz R; Marín L; Alcoceba M; Chillón MC; Balanzategui A; Santamaria C; Rosiñol L; de la Rubia J; Hernandez MT; Garcia-Navarro I; Lahuerta JJ; González M; San Miguel JF
Blood; 2008 Oct; 112(7):2709-12. PubMed ID: 18594024
[TBL] [Abstract][Full Text] [Related]
3. Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis.
Zhong DN; Wu JZ; Li GJ
Acta Haematol; 2013; 129(2):90-5. PubMed ID: 23171856
[TBL] [Abstract][Full Text] [Related]
4. New approach to analyze genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw.
Balla B; Vaszilko M; Kósa JP; Podani J; Takács I; Tóbiás B; Nagy Z; Lazáry A; Lakatos P
Oral Dis; 2012 Sep; 18(6):580-5. PubMed ID: 22339777
[TBL] [Abstract][Full Text] [Related]
5. Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.
Kastritis E; Melea P; Bagratuni T; Melakopoulos I; Gavriatopoulou M; Roussou M; Migkou M; Eleutherakis-Papaiakovou E; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Oct; 58(10):2304-2309. PubMed ID: 28604257
[TBL] [Abstract][Full Text] [Related]
6. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.
Taş Ozyurtseven B; Serin I; Nursal AF; Pehlivan S; Pehlivan M
BMC Oral Health; 2021 May; 21(1):272. PubMed ID: 34006261
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.
Sarasquete ME; González M; San Miguel JF; García-Sanz R
Oral Dis; 2009 Sep; 15(6):382-7. PubMed ID: 19413677
[TBL] [Abstract][Full Text] [Related]
8. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.
Guo Z; Cui W; Que L; Li C; Tang X; Liu J
Int J Oral Maxillofac Surg; 2020 Mar; 49(3):298-309. PubMed ID: 31445964
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Katz J; Gong Y; Salmasinia D; Hou W; Burkley B; Ferreira P; Casanova O; Langaee TY; Moreb JS
Int J Oral Maxillofac Surg; 2011 Jun; 40(6):605-11. PubMed ID: 21396799
[TBL] [Abstract][Full Text] [Related]
11. SIRT1/HERC4 Locus Associated With Bisphosphonate-Induced Osteonecrosis of the Jaw: An Exome-Wide Association Analysis.
Yang G; Hamadeh IS; Katz J; Riva A; Lakatos P; Balla B; Kosa J; Vaszilko M; Pelliccioni GA; Davis N; Langaee TY; Moreb JS; Gong Y
J Bone Miner Res; 2018 Jan; 33(1):91-98. PubMed ID: 28856724
[TBL] [Abstract][Full Text] [Related]
12. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.
English BC; Baum CE; Adelberg DE; Sissung TM; Kluetz PG; Dahut WL; Price DK; Figg WD
Ther Clin Risk Manag; 2010 Nov; 6():579-83. PubMed ID: 21151627
[TBL] [Abstract][Full Text] [Related]
13. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw.
Stockmann P; Nkenke E; Englbrecht M; Schlittenbauer T; Wehrhan F; Rauh C; Beckmann MW; Fasching PA; Kreusch T; Mackensen A; Wullich B; Schett G; Spriewald BM
J Craniomaxillofac Surg; 2013 Jan; 41(1):71-5. PubMed ID: 23218978
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation.
Then C; Hörauf N; Otto S; Pautke C; von Tresckow E; Röhnisch T; Baumann P; Schmidmaier R; Bumeder I; Oduncu FS
Onkologie; 2012; 35(11):658-64. PubMed ID: 23147542
[TBL] [Abstract][Full Text] [Related]
15. Experience with the treatment of bisphosphonate-related osteonecrosis of the jaw.
Janovska Z; Mottl R; Slezak R
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):313-7. PubMed ID: 24108250
[TBL] [Abstract][Full Text] [Related]
16. SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw.
Yang G; Collins JM; Rafiee R; Singh S; Langaee T; McDonough CW; Holliday LS; Wang D; Lamba JK; Kim YS; Pelliccioni GA; Vaszilko M; Kosa JP; Balla B; Lakatos PA; Katz J; Moreb J; Gong Y
J Bone Miner Res; 2021 Feb; 36(2):347-356. PubMed ID: 32967053
[TBL] [Abstract][Full Text] [Related]
17. The care and management of bisphosphonate--associated osteonecrosis of the jaw in the patient with multiple myeloma: a case study.
Teah MJ; Syme SL; Scheper M; Weikel DS
J Dent Hyg; 2013 Aug; 87(4):181-7. PubMed ID: 23986411
[TBL] [Abstract][Full Text] [Related]
18. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
[TBL] [Abstract][Full Text] [Related]
19. Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw.
Allegra A; Mania M; D'Ascola A; Oteri G; Siniscalchi EN; Avenoso A; Innao V; Scuruchi M; Allegra AG; Musolino C; Campo S
Biomed Res Int; 2020; 2020():9879876. PubMed ID: 32714991
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
Junquera S; Álvarez-Yagüe E; Junquera L; Ugalde R; Rúa L
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):523-526. PubMed ID: 31863926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
